1. Home
  2. TYRA vs FAX Comparison

TYRA vs FAX Comparison

Compare TYRA & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • FAX
  • Stock Information
  • Founded
  • TYRA 2018
  • FAX 1986
  • Country
  • TYRA United States
  • FAX United States
  • Employees
  • TYRA N/A
  • FAX N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • FAX Investment Managers
  • Sector
  • TYRA Health Care
  • FAX Finance
  • Exchange
  • TYRA Nasdaq
  • FAX Nasdaq
  • Market Cap
  • TYRA 681.7M
  • FAX 672.5M
  • IPO Year
  • TYRA 2021
  • FAX N/A
  • Fundamental
  • Price
  • TYRA $15.30
  • FAX $15.52
  • Analyst Decision
  • TYRA Strong Buy
  • FAX
  • Analyst Count
  • TYRA 7
  • FAX 0
  • Target Price
  • TYRA $30.71
  • FAX N/A
  • AVG Volume (30 Days)
  • TYRA 160.3K
  • FAX 833.6K
  • Earning Date
  • TYRA 11-06-2025
  • FAX 01-01-0001
  • Dividend Yield
  • TYRA N/A
  • FAX 12.09%
  • EPS Growth
  • TYRA N/A
  • FAX N/A
  • EPS
  • TYRA N/A
  • FAX N/A
  • Revenue
  • TYRA N/A
  • FAX N/A
  • Revenue This Year
  • TYRA N/A
  • FAX N/A
  • Revenue Next Year
  • TYRA N/A
  • FAX N/A
  • P/E Ratio
  • TYRA N/A
  • FAX N/A
  • Revenue Growth
  • TYRA N/A
  • FAX N/A
  • 52 Week Low
  • TYRA $6.42
  • FAX $2.33
  • 52 Week High
  • TYRA $29.60
  • FAX $2.84
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 69.86
  • FAX 26.01
  • Support Level
  • TYRA $13.29
  • FAX $15.70
  • Resistance Level
  • TYRA $13.98
  • FAX $15.86
  • Average True Range (ATR)
  • TYRA 0.68
  • FAX 0.19
  • MACD
  • TYRA 0.09
  • FAX -0.07
  • Stochastic Oscillator
  • TYRA 91.65
  • FAX 3.54

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

Share on Social Networks: